Activin receptors in human cancer: Functions, mechanisms, and potential clinical applications

Biochem Pharmacol. 2024 Feb 16;222:116061. doi: 10.1016/j.bcp.2024.116061. Online ahead of print.ABSTRACTActivins are members of the transforming growth factor-β (TGF-β) superfamily and act as key regulators in various physiological processes, such as follicle and embryonic development, as well as in multiple human diseases, including cancer. They have been established to signal through three type I and two type II serine/threonine kinase receptors, which, upon ligand binding, form a final signal-transducing receptor complex that activates downstream signaling and governs gene expression. Recent research highlighted the dysregulation of the expression or activity of activin receptors in multiple human cancers and their critical involvement in cancer progression. Furthermore, expression levels of activin receptors have been associated with clinicopathological features and patient outcomes across different cancers. However, there is currently a paucity of comprehensive systematic reviews of activin receptors in cancer. Thus, this review aimed to consolidate existing knowledge concerning activin receptors, with a primary emphasis on their signaling cascade and emerging biological functions, regulatory mechanisms, and potential clinical applications in human cancers in order to provide novel perspectives on cancer prognosis and targeted therapy.PMID:38369212 | DOI:10.1016/j.bcp.2024.116061
Source: Biochemical Pharmacology - Category: Drugs & Pharmacology Authors: Source Type: research